Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enro
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
08:00pm, Wednesday, 23'rd Apr 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data fr
HUTCHMED shares rise 10% as Phase II gastric cancer trial hits key milestone
04:12am, Tuesday, 22'nd Apr 2025
Shares in Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013) rose 10% in early trading on Tuesday after the biopharma company announced it had completed patient enrolment for a key phase II trial o
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
08:00pm, Monday, 21'st Apr 2025
HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of the r
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
04:15pm, Monday, 14'th Apr 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial.
3 Internet Delivery Services Stocks in Focus Amid Industry Challenges
11:00am, Tuesday, 08'th Apr 2025
Tariff war, inflationary pressure and still-high interest rates are major concerns for the Zacks Internet - Delivery Services industry. However, efforts to adopt consumer preferences and technological
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
12:27pm, Wednesday, 02'nd Apr 2025
Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyo
– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated subs
BOULDER, Colo. , March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team wil
Terrestrial Energy to Become First Publicly Traded Molten Salt Nuclear Reactor Developer Through Combination with HCM II Acquisition Corp.
09:30am, Wednesday, 26'th Mar 2025
CHARLOTTE, N.C. and STAMFORD, Conn., March 26, 2025 (GLOBE NEWSWIRE) -- Terrestrial Energy Inc., a developer of small modular nuclear power plants using advanced reactor technology, and HCM II Acquisi
AI Becoming Essential to HCM, ISG Says
09:48am, Friday, 21'st Mar 2025
STAMFORD, Conn.--(BUSINESS WIRE)---- $III #AI--AI is becoming central to HCM and employee engagement, with two-thirds of enterprises expected to need AI-enabled capabilities by 2027, ISG says.
— First and only EZH2 inhibitor approved by the NMPA — — HUTCHMED's fourth product, and its first approval in hematological malignancies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Marc
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
05:30am, Thursday, 20'th Mar 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr
US pharma restrictions won't affect Hutchmed operations, says CEO
12:46am, Thursday, 20'th Mar 2025
Weiguo Su, CEO of Chinese pharma company HUTCHMED, talks about the company's latest earnings report, and why it's positioned to be 'sustainably profitable' from this point despite some external chal
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
08:00pm, Wednesday, 19'th Mar 2025
— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO ® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to addre
